LakePharma Announces Dedicated Vector Center to Support Gene and Cell Therapy
SAN CARLOS, Calif. and WORCESTER, Mass., Feb. 26, 2019 /PRNewswire/ -- LakePharma, Inc., the leading US-based biologics contract research, development, and manufacturing organization (CRDMO), announced today its Vector Center is now commercially operational. The center offers a comprehensive range of services including viral vector construction, CAR-T and stable cell line engineering, preclinical process development, scale-up production, and analytical development. Three viral production systems—lentivirus, adeno-associated virus (AAV), and baculovirus—are available. The center is located in Worcester, MA, which is in close proximity to the Cambridge and Boston areas.
"LakePharma has been producing viral vectors and engineering cells in our California and Massachusetts facilities for many years. However, with the tremendous advances in gene and cell therapy, we recognized the need for a center of excellence to support the industry," commented Norman Garceau, Vice President of Technical Operations for LakePharma. "Since its founding, LakePharma has been relentless in capability expansion and service integration to provide our valued clients with end-to-end solutions. The dedication of the Vector Center to support the burgeoning gene and cell therapy fields is yet another example of our commitment," said Hua Tu, LakePharma's CEO.
LakePharma collaborates on projects at all stages of biologics development from discovery, preclinical process development, to cGMP manufacturing for Phase I/II clinical trials. With its Vector Center operational, the company now provides fully integrated solutions from viral vector design to process development and scale-up production.
To learn more, please visit https://lakepharma.com/services/viral-vector-services
View original content to download multimedia:http://www.prnewswire.com/news-releases/lakepharma-announces-dedicated-vector-center-to-support-gene-and-cell-therapy-300801630.html
SOURCE LakePharma, Inc.